The state-of-the-art in predictive toxicogenomics.

Curr Opin Drug Discov Devel

Iconix Pharmaceuticals, 325 East Middlefield Road, Mountain View, CA 94043, USA.

Published: January 2006

Predictive toxicogenomics, ie, the acquisition of advanced knowledge of the safety profile of a compound using genomic biomarkers, is a technology that provides much optimism for improving early drug discovery decisions. Toxicogenomics creates an opportunity to shift attrition to earlier stages in drug development to a point where course-corrective action can be taken with relatively lower financial costs, thus improving the efficiency of the drug development process. This review will survey the current state-of-the-art in toxicogenomics for predicting toxicity, both in vivo and in vitro, with emphasis on the use of classification algorithms and the importance of toxicogenomic databases for biomarker discovery and validation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

predictive toxicogenomics
8
drug development
8
state-of-the-art predictive
4
toxicogenomics
4
toxicogenomics predictive
4
toxicogenomics acquisition
4
acquisition advanced
4
advanced knowledge
4
knowledge safety
4
safety profile
4

Similar Publications

Surgery remains the primary treatment for solid malignant tumors, but controlling postoperative tumor recurrence and metastasis continues to be a major challenge. Understanding the factors that influence tumor recurrence and metastasis after surgery, as well as the underlying biological mechanisms, is critical. Previous studies suggest that anesthetic agents may increase the risk of tumor recurrence and metastasis in patients with cancer, but the mechanisms underlying these findings remain unclear.

View Article and Find Full Text PDF

Benchmarking is an important step in the improvement, assessment, and comparison of the performance of drug discovery platforms and technologies. We revised the existing benchmarking protocols in our Computational Analysis of Novel Drug Opportunities (CANDO) multiscale therapeutic discovery platform to improve utility and performance. We optimized multiple parameters used in drug candidate prediction and assessment with these updated benchmarking protocols.

View Article and Find Full Text PDF

Novel perspective on particulate matter and Alzheimer's disease: Insights from adverse outcome pathway framework.

Environ Pollut

January 2025

Joint International Research Laboratory of Environment and Health, Ministry of Education, Guangdong Provincial Engineering Technology Research Center of Environmental Pollution and Health Risk Assessment, Department of Occupational and Environmental Health, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China. Electronic address:

Alzheimer's disease (AD) is a neurodegenerative disease, that accounts for 50-75% of all dementia cases. Evidence demonstrates the link between particulate matter (PM) exposure and AD. However, there are still considerable research gaps.

View Article and Find Full Text PDF

Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report.

Forensic Sci Int Genet

December 2024

Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, France.

Interpreting postmortem concentrations of 3,4-Methylenedioxymethamphetamine (MDMA) remains challenging due to the wide range of reported results and the potential idiosyncratic nature of MDMA toxicity. Consequently, forensic pathologists often rely on a body of evidence to establish conclusions regarding the cause and the manner of death in death involving MDMA. Given these issues, implementing pharmacogenetics' (PGx)' testing may be beneficial.

View Article and Find Full Text PDF

Background: Per- and polyfluoroalkyl substances (PFAS) are human-made chemicals that accumulate in the human body and the environment over time. Humans are primarily exposed to PFAS through drinking water, food, consumer products, and dust. These exposures can have many adverse health effects, including cardiovascular diseases (CVDs) and factors contributing to CVDs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!